Dossier
pomalidomide
Coverage of pomalidomide in the Nexus archive.
- Talquetamab Regimens Boost Survival in Multiple Myeloma
A phase III trial showed that Talquetamab (Talvey) combined with daratumumab (Darzalex) and optionally pomalidomide (Pomalyst) significantly improved survival outcomes for patients with relapsed or refractory multiple myeloma compared to an active regimen.